Mapping health outcome measures from a stroke registry to eq-5d weights

Ghatnekar, Ola; Eriksson, Marie; Glader, Eva Lotta

doi:10.1186/1477-7525-11-34

Cited by 13 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consonant with the actions listed, the first A (Ask) consists in understanding beliefs and values, knowledge (14)(15)(16)(17)(18) and the behaviors of the people in sanitary and motivational areas. Within the Community area, one should understand the health condition of the person and what their ability to self-monitoring.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Strategies for self-management support by patients with stroke: integrative review

Morais

Gonzaga

Aquino

et al. 2015

Rev. esc. enferm. USP

View full text Add to dashboard Cite

Objective:To analyze strategies for self-management support by patients with stroke in the light of the methodology of the five A's (ask, advice, assess, assist and arrange). Methods: Integrative review conducted at the following databases CINAHL, SCOPUS, PubMed, Cochrane and LILACS. Results: A total of 43 studies published between 2000 and 2013 comprised the study sample. All proposed actions in the five A's methodology and others were included. We highlight the Assist and Arrange, in which we added actions, especially with regard to the use of technological resources and joint monitoring between patients, families and professionals. No study included all five A's, which suggests that the actions of supported self-management are developed in a fragmented way. Conclusion: The use of five A's strategy provides guidelines for better management of patients with stroke with lower cost and higher effectiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Follow up patients (20,31,44,51) through questionnaires to assess activities of daily living, self-management and quality of life continuously (16) *.…”

Section: Arrangementioning

confidence: 99%

Strategies for self-management support by patients with stroke: integrative review

Morais

Gonzaga

Aquino

et al. 2015

Rev. esc. enferm. USP

View full text Add to dashboard Cite

show abstract

“…Data from patients with cerebral infarction, IS, haemorrhagic stroke (intracranial, intracerebral or subarachnoid) or TIA were collected by 21 studies, 102,103,[112][113][114][115][116][117][118][119][120][121][122][123][124][125][126][127][128][129][130] and data on patients specifically with AF (with or without stroke) were collected in six studies. 112,113,121,[131][132][133] Four of the included studies also provided data for patients with MI 103,113,121,131 and two assessed the impact of additional bleeding events.…”

Section: Health-related Quality-of-life Evidencementioning

confidence: 99%

“…EQ-5D responses were converted into utilities using UK population tariffs developed by Dolan 134 in nine studies. 102,103,117,[122][123][124]127,128,131 Two of those studies were undertaken in the UK. 102,132 The remaining studies were undertaken in Canada, Finland, Germany, Korea, Norway, Poland, Spain, Sweden, the USA, the Netherlands or in multiple countries.…”

Section: Health-related Quality-of-life Evidencementioning

confidence: 99%

See 1 more Smart Citation

Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation

Edwards

Wakefield

Jhita

et al. 2020

Health Technol Assess

View full text Add to dashboard Cite

Background Cryptogenic stroke is a stroke for which no cause is identified after standard diagnostic tests. Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants. Objectives The objectives were to assess the diagnostic test accuracy, clinical effectiveness and cost-effectiveness of three implantable monitors [BioMonitor 2-AF™ (Biotronik SE & Co. KG, Berlin, Germany), Confirm Rx™ (Abbott Laboratories, Lake Bluff, IL, USA) and Reveal LINQ™ (Medtronic plc, Minneapolis, MN, USA)] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring. Data sources MEDLINE, EMBASE, The Cochrane Library, Database of Abstracts of Reviews of Effects and Health Technology Assessment databases were searched from inception until September 2018. Review methods A systematic review was undertaken. Two reviewers agreed on studies for inclusion and performed quality assessment using the Cochrane Risk of Bias 2.0 tool. Results were discussed narratively because there were insufficient data for synthesis. A two-stage de novo economic model was developed: (1) a short-term patient flow model to identify cryptogenic stroke patients who have had atrial fibrillation detected and been prescribed anticoagulation treatment (rather than remaining on antiplatelet treatment) and (2) a long-term Markov model that captured the lifetime costs and benefits of patients on either anticoagulation or antiplatelet treatment. Results One randomised controlled trial, Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL-AF) (Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478–86), was identified, and no diagnostic test accuracy study was identified. The CRYSTAL-AF trial compared the Reveal™ XT (a Reveal LINQ predecessor) (Medtronic plc) monitor with standard of care monitoring. Twenty-six single-arm observational studies for the Reveal devices were also identified. The only data for BioMonitor 2-AF or Confirm Rx were from mixed population studies supplied by the companies. Atrial fibrillation detection in the CRYSTAL-AF trial was higher with the Reveal XT than with standard monitoring at all time points. By 36 months, atrial fibrillation was detected in 19% of patients with an implantable cardiac monitor and in 2.3% of patients receiving conventional follow-up. The 26 observational studies demonstrated that, even in a cryptogenic stroke population, atrial fibrillation detection rates are highly variable and most cases are asymptomatic; therefore, they probably would not have been picked up without an implantable cardiac monitor. Device-related adverse events, such as pain and infection, were low in all studies. The de novo economic model produced incremental cost effectiveness ratios comparing implantable cardiac monitors with standard of care monitoring to detect atrial fibrillation in cryptogenic stroke patients based on data for the Reveal XT device, which can be related to Reveal LINQ. The BioMonitor 2-AF and Confirm RX were included in the analysis by making a strong assumption of equivalence with Reveal LINQ. The results indicate that implantable cardiac monitors could be considered cost-effective at a £20,000–30,000 threshold. When each device is compared incrementally, BioMonitor 2-AF dominates Reveal LINQ and Confirm RX. Limitations The cost-effectiveness analysis for implantable cardiac monitors is based on a strong assumption of clinical equivalence and should be interpreted with caution. Conclusions All three implantable cardiac monitors could be considered cost-effective at a £20,000–30,000 threshold, compared with standard of care monitoring, for cryptogenic stroke patients with no atrial fibrillation detected after 24 hours of external electrocardiographic monitoring; however, further clinical studies are required to confirm their efficacy in cryptogenic stroke patients. Study registration This study is registered as PROSPERO CRD42018109216. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 5. See the NIHR Journals Library website for further project information.

show abstract

Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy

Flint

Medjedovic²,

O’Flaherty³

et al. 2022

Eur J Health Econ

View full text Add to dashboard Cite

Mapping health outcome measures from a stroke registry to eq-5d weights

Cited by 13 publications

References 32 publications

Strategies for self-management support by patients with stroke: integrative review

Strategies for self-management support by patients with stroke: integrative review

Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation

Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy

Contact Info

Product

Resources

About